Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Agrippal S1 2009-2010 seasonal influenza vaccine in adults and elderly subjects
2009-010598-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza vaccine, inactivated, surface antigen in influenza (2 arms), sponsored by Novartis. Primary endpoints: Immunogenicity in non-elderly adults by strain, Immunogenicity in elderly subjects by strain and 2 more. Started Apr 2009; status: completed.
02
Drugs
influenza vaccine, inactivated, surface antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2009-010598-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010598-19.